Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Capped RNAs synthesized by in vitro transcription have found wide utility for studying mRNA function and metabolism and for producing proteins of interest. We characterize here a recently synthesized series of cap analogs with improved properties that contain a sulfur substitution for a nonbridging oxygen in either the α-, β-, or γ-phosphate moieties, m 27,2′-OGppp S G, m 27,2′-OGpp S pG, and m 27,2′-OGp S ppG, respectively. The new compounds were also modified at the 2′-O position of the m 7 Guo to make them anti-reverse cap analogs (ARCAs), i.e., they are incorporated exclusively in the correct orientation during in vitro transcription. Each of the S-ARCAs exists in two diastereoisomeric forms (D1 and D2) that can be resolved by reverse-phase HPLC. A major in vivo pathway for mRNA degradation is initiated by removal of the cap by the pyrophosphatase Dcp1/Dcp2, which cleaves between the α- and β-phosphates. Oligonucleotides capped with m 27,2′-OGpp S pG (D2) were completely resistant to hydrolysis by recombinant human Dcp2 in vitro, whereas those capped with m 27,2′-OGpp S pG (D1) and both isomers of m 27,2′-OGppp S G were partially resistant. Luciferase mRNA capped with m 27,2′-OGpp S pG (D2) had a t1/2 of 257 min in cultured HC11 mammary epithelial cells compared with 86 min for m 7 Gp 3 G-capped mRNA. Luciferase mRNAs capped with m 27,2′-OGpp S pG (D1) and m 27,2′-OGpp S pG (D2) were translated 2.8-fold and 5.1-fold, respectively, more efficiently in HC11 cells than those capped with m 7 Gp 3 G. The greater yield of protein due to combining higher translational efficiency with longer t1/2 of mRNA should benefit applications that utilize RNA transfection such as protein production, anti-cancer immunization, and gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Messenger RNA degradation in eukaryotes
Sachs, A. B. (1993) · Cell · doi:10.1016/0092-8674(93)80043-e · Cited by 846 · cited 1×
“…cap is one determinant of mRNA decay, protecting it from degradation by 59/39 exonucleases in both the cytosol and nucleus (Hsu and Stevens 1993; Sachs 1993; Walther et al. 1998). mRNA degradation in eukaryotic cells is essential for the control of gene expression and elimination of aberrant…”
BackgroundDifferential Inhibition of mRNA Degradation Pathways by Novel Cap Analogs
Grudzien, E., Kalek, M., Jemielity, J., Darzynkiewicz, E., & Rhoads, R. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509121200 · Cited by 90 · cited 7×
“This resulted in a translational efficiency that was only 68% that of m2 7,39-OGp3G in the RRL system and 52% in cultured cells (Grudzien et al. 2006).”
BackgroundMethodResultSelf-citationAnderson, D. M., Hall, L. L., Ayyalapu, A. R., Irion, V. R., Nantz, M. H., & Hecker, J. G. (2003) · Human Gene Therapy · doi:10.1089/10430340360535751 · Cited by 66 · cited 1×
“Such RNAs can be introduced not only into cultured cells but also into living animals through delivery systems that protect the RNA against degradation (Anderson et al. 2003; Zohra et al. 2005).”
Background
Cited by
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
“ARCAs juxtaposing the traditional cap analogues have been shown to exhibit more than four times RNA transcription efficiency [44].”
BackgroundThe promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498
“[52] [53] [54] Optimization of the carrier system can provide significant benefit as well.”
BackgroundThe challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368
The Role of the Phosphorus Atom in Drug Design
Rodriguez, J. B., & Gallo‐Rodriguez, C. (2019) · ChemMedChem · doi:10.1002/cmdc.201800693 · Cited by 267
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
“A new class of ARCA caps has been established that contains a phosphorothioate bond [58].”
BackgroundKuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226
Self-citationKwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Biomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Sikorski, P. J., Warminski, M., Kubacka, D., Ratajczak, T., Nowis, D., Kowalska, J., & Jemielity, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa032 · Cited by 142
Self-citationNanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.
Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95
“Luciferase mRNA that was capped using S-ARCAs resulted in a higher translational efficiency and a longer half-life in cultured HC11 cells than mRNA capped with the original 7-methyl guanosine (m7GpppG) [56].”
BackgroundChemical Modifications of mRNA Ends for Therapeutic Applications
Warminski, M., Mamot, A., Depaix, A., Kowalska, J., & Jemielity, J. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00442 · Cited by 91
“43,44 The D1 diastereomer bound to eIF4E with 4-fold higher affinity than the unmodified ARCA and RNAs capped with β -”
BackgroundSelf-citationSynthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Viral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Selection of UTRs in mRNA-Based Gene Therapy and Vaccines
Volkhin, I. A., Paremskaia, A. I., Dashian, M. A., Smeshnova, D. S., Pavlov, R. E., Mityaeva, O. N., Volchkov, P. Y., & Deviatkin, A. A. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604659 · Cited by 7
Metadata
- Authors
- Grudzien-Nogalska, E., Jemielity, J., Kowalska, J., Darzynkiewicz, E., & Rhoads, R. E.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2007-08-24
- Volume
- 13
- Issue
- 10
- Pages
- 1745-1755
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2126865761
- Cited by
- 152
- References
- 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.